1435 jerome coffey nhc

Dr Jerome Coffey MD FRCPI FRCR FFRRCSIInterim Director, NCCP

National Healthcare ConferenceDublin, May 28th 2015

Cancer 2020

Challenges Solutions Strategy Action

The Challenge

Dr Susan O’Reilly MB, FRCPC, FRCPI

Photo courtesy of David Branigan, Oceansport

Cancer Projections for Ireland 2015–2040

2015 2020 2025 2030 2035 2040

% increase 2010 -2040

Females 14322 16172 18202 20295 22368 24287 84%

Males 17008 19692 22658 25775 28855 31704 107%

Total 31330 35864 40860 46070 51223 55991 97%

www.ncri.ie

Email: [email protected] Tel: +44 (0)28 9063 2573 Website: www.qub.ac.uk/nicr

0

20

40

60

80

100

120

140

1 2 3 4 5

Deprivation Quintile

Incidence-Males

Incidence-Females

Mortality-Males

Mortality-Females

least deprived

most deprived

0

2

4

6

8

10

12

14

16

18

1 2 3 4 5

Deprivation Quintileleast deprived

most deprived

0

5

10

15

20

25

30

1 2 3 4 5

Deprivation QuintileEA

SR p

er 1

00,0

00least

deprivedmost

deprived

Lung Cervix Stomach

Deprivation & Cancer

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries

(CONCORD-2)

Claudia Allemani, PhD, Hannah K Weir, PhD, Helena Carreira, MPH, Rhea Harewood, MSc, Devon Spika, MSc, Xiao-Si Wang, PhD, Finian Bannon, PhD, Jane V Ahn, MSc, Christopher J Johnson, MPH, Audrey Bonaventure, MD, Rafael Marcos-

Gragera, PhD, Charles Stiller, MSc, Gulnar Azevedo e Silva, ProfMD, Wan-Qing Chen, PhD, Olufemi J Ogunbiyi, ProfFWACP, Bernard Rachet, FFPH, Matthew J Soeberg, PhD, Hui You, MAppStats, Tomohiro Matsuda, PhD, Magdalena

Bielska-Lasota, ProfMD, Hans Storm, MD, Thomas C Tucker, ProfPhD, Michel P Coleman, ProfFFPH

The Lancet Volume 385, Issue 9972, Pages 977-1010 (March 2015)

DOI: 10.1016/S0140-6736(14)62038-9

Copyright © 2015 Allemani et al.

Revealed: Irish cancer survival rates lowest in Europe

03:55, 19 April 2015 by Susan MitchellCancer survival rates in Ireland are amongst the lowest in Europe, new figures show. The figures were laid bare in a major global report that represents the most comprehensive international comparison of cancer survival to date. Cancer survival rates for common cancers – including breast cancer, cervical cancer, ovarian cancer and rectal cancer – were the lowest of all comparable 16 countries examined by this newspaper.

http://www.businesspost.ie

The unsolvable mystery of our low cancer survival rates

03:55, 19 April 2015 by Susan MitchellMillions have been invested in cancer care in Ireland, but we continue to lag behind the rest of Europe on survival rates. Despite the efforts made by successive governments, the National Cancer Control Programme and the HSE to raise cancer survival rates, Ireland has failed to catch up with other European countries…

http://www.businesspost.ie

Irish government deficit compared to other European countries and the US

wikipedia.org/wiki/European_debt_crisis

http://www.tradingeconomics.com/ireland/government-debt-to-gdp

Cancer Drug Expenditure

€0

€50,000,000

€100,000,000

€150,000,000

€200,000,000

€250,000,000

2009 2010 2011 2012 2013 2014*

Hospital

Community

Solutions

Cell 161, 1215-1228, May 21, 2015

Copyright © Evinance Innovation Inc. 2015

Our platform reduces costs & improves quality by enabling evidence-based decision making

May 2015contact: [email protected]


Evinance

Workflow Adherence

Decision Support

ClinicalTrials

Guidelines

Patient Data

EHR CIS


Clinical Consult Note


Prompts


Recommendations


Real-Time Dashboards


Patient Paths

Pt. X

Strategy

• Cancer surgery delivered in 32 hospitals • Low volumes, poor outcomes, cancer scandals: delayed Dx / Tx• Lack of focus on Primary Care and patient pathways• No co-ordinated national plan for screening, surgery, radiation,

medical oncology• Eight Autonomous Health Boards

Small health boards did not have the population to support specialist cancer services

Some health boards had 3 or more competing hospitals of equal size and status

• Delays in service developments

Prior to 2006

slide courtesy Dr. Marie Laffoy

Ireland will have:

• A system of cancer control which will reduce cancer incidence, morbidity and mortality rates relative to other EU 15 countries by 2015

• A network of equitably accessible state-of-the-art cancer treatment facilities.

• We will become an internationally recognised location for education and research into all aspects of cancer.

• Irish people will know and practice health-promoting and cancer preventing behaviours and will have increased awareness of and access to early cancer detection and screening.

2nd National Cancer Strategy

slide courtesy Dr. Marie Laffoy

“National Cancer Strategy 2006:A Strategy for Cancer Control in

Ireland”

Evaluation Panel Report

Warde et al

The NCCP will continue to implement the strategy for cancer control and to plan, support and monitor the delivery of cancer services

nationally.

Top 5 in 2015

1. Audit, Quality & Risk Forums: Breast, Lung, Prostate & Pancreas

2. National Medical Oncology Clinical Information System

3. Launch of Breast and Prostate cancer evidence-based clinical practice guidelines

4. Partnership with National Cancer Screening Service

5. Pilot single KPI for wait times for elective cancer surgeries

Developments 2015

Priority posts:

1. National Lead Hereditary Cancer Service, NCCP & SJH

2. Medical Oncologists x 2

3. Specialist Oncology Nurses (CNS/ANP level) x 2

4. Urologist x 1 (S/SW Hospital Group)

5. Second Paediatric Radiation Oncologist, SLRON & OLCHC

Funded Service Developments 2015 (2)

Capital:1. Additional linear accelerators x 2, St. Luke’s Hospital2. Initial planning and design work, St. Luke’s Centre at Beaumont3. Cross-border project in Altnagelvin

Community Oncology:4. Support and deliver cancer education and training programmes.5. Pilot and Implement a Survivorship Patient Treatment Summary

and Long-term Care Plan

Medium & Longer Term

Data Culture: Quality & Outcomes

Centralisation of Surgical Oncology* Expansion of Medical Oncology Radiation Oncology in Altnagelvin, Cork, Galway & Dublin

National Oncology Drug Management System (estd. 2011) Oncology Medication Safety Review (estd. 2014)

NCCP Alignment with Clinical Strategy & Programmes Division NCCP Alignment with Hospital Groups, CHOs Molecular Diagnostics Strategy

The Next Ten Years

Plan for growth in incidence, prevalence & complexity

Resolve the gaps in clinical and allied health staffing

Invest in molecular diagnostic and personalised medicine

Emphasise research, innovation and productivity

Foster prevention and screening

Focus on survivorship

1435 jerome coffey nhc

Healthcare

Transcript of 1435 jerome coffey nhc